A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.

@article{MaisonBlanche2013ARD,
  title={A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.},
  author={Pierre Maison-Blanche and Jan Baptist Vermorken and Tuncay Goksel and Jean-Pascal Machiels and Sanjiv S. Agarwala and Sylvie Rottey and Gedske Daugaard and Constantin Volovat and Max Ernst Scheulen and Lisa Sengel\ov and Dana Grecea and Alexandru Eniu and E. P. Jaeger and Eyal Meiri and Stefano Cascinu and Dirk Strumberg and Gokhan Demir and Michael Clemens and Graziella Pinotti and Mario Nardi and Troy Guthrie and Emmanuelle Boelle and Emmanuelle Magherini},
  journal={Journal of cardiovascular pharmacology},
  year={2013},
  volume={61 6},
  pages={495-504}
}
: The effect of repeated doses of aflibercept on ventricular repolarization in cancer patients was evaluated in an intensive electrocardiogram trial. This randomized, placebo-controlled, double-blind trial was conducted in 87 treated solid tumor patients. Treatment was with 6 mg/kg aflibercept, 1-hour intravenous (n = 43), or placebo (n = 44), combined with ≤75 mg/m docetaxel, every 3 weeks. Electrocardiograms were collected for 6 hours posttreatment using digital 12-lead Holter recorders, at… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 9 times. VIEW TWEETS

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…